2024.1 MCQ Flashcards
2024.1
1) A medication that would be acceptable to a patient who refuses all products derived from human plasma is
a) albumin
b) F7
c) Fib conc
d) PT complex
recombinant F7
a) albumin (from plasma)
b) F7 (recombinant lab made)
c) Fib conc(from freeze dried plasma) d) PT complex (from plasma)
“https://www.bjanaesthesia.org.uk/action/showFullTableHTML?isHtml=true&tableId=AEV161TB1&pii=S0007-0912%2817%2931069-3
BJA artice of table of whats not ok and whats ok”
2024.1
2) An adult patient undergoing cardiac surgery exhibits excessive bleeding following cardiopulmonary bypass. A thromboelastogram performed on their blood is shown below. The most likely cause of the bleeding is
a) Platelets
b) Fibrinogen
c) Cryo
d) FFP
Platelets (ie reduced max amp, thin sausage)
LITFL DP CSL
2024.1
3) A term neonate is undergoing closure of gastroschisis under general anaesthesia with pressure control ventilation via an endotracheal tube. The estimated blood loss is 10 mL. Fluid therapy has been 4% albumin 40 mL/kg in addition to maintenance 10% dextrose 4 mL/kg/h. During closure of the defect, the oxygen saturation falls to 80%. The most likely cause of the desaturation is
a)Pulmonary oedema/excessive fluids
b) Reduced Lung compliance
c) Shunt
d) FiO2 too low
b) Reduced Lung compliance
UTD
2024.1
4) Phaeochromocytoma commonly presents with all of the following EXCEPT
a) RVH/ failure
b) stress induced cardiomyopathy
c)Pulmonary HTN
d) long QT (and VTs)
e) ST changes
f) Cardiomyopathy
c) Pulmonary HTN
a) RVH/ failure yes,
b)stress induced cardiomyopathy
c)Pulmonary HTN
d) long QT (and VTs)
e) ST changes. yes 2o ischaemia from HTN/ supply demand mismatch
f) Cardiomyopathy. yes 2o HTN
Unclear recalled options, list of sx
UTD
2024.1
5) 5. Duchenne muscular dystrophy is NOT associated with
No sux or VA
** Resistant to NDMR (can give, generally delayed onset, prolonged duration)
** Female carriers dont usually have CM”
2024.1
6) 6. When administered in combination with tramadol, the agent considered highest risk for the development of serotonin syndrome is
a) moclobemide
b) escitalopram
c) desvenlafaxine
d) tapentadol
e) TCAs”
a) moclobemide
Tramadol + MAOIs = CI because high risk serotonin syndrome!
“NPS Org - https://www.nps.org.au/assets/AP/pdf/p41-Perananthan-Buckley.pdf
2024.1
7) 7. The action of methylene blue in treating vasoplegia is mediated by
“a) inhib GNP
b) inhib indicible nitric oxidase
c) inhib constitutive nictric oxidase
d) binds to vasopressin recep
e) binds to angiotensin 2”
a) inhib GNP
https://academic.oup.com/ejcts/article/28/5/705/502264
2024.1
8) 8. A stellate ganglion block is NOT indicated in the management of
“sympathetically mediated pain from the head, neck and upper extremities
- reflex sympathetic dystrophy
- herpes zoster
vasospasm
- Raynaud disease
- temporal arteritis
- Buerger disease
hyperhidrosis
electrical storm 7
- three or more ventricular arrhythmias within 24 hours requiring defibrillation or overdrive pacing –> a left-sided (or bilateral) stellate ganglion block is preferred in this context 8
Contraindications are current coagulopathy, recent myocardial infarction, pathologic bradycardia, and glaucoma, contralateral phrenic nerve palsy”
2024.9. Obstructive sleep apnoea in children is diagnosed with an apnoea-hypopnoea index (AHI) of at least
a) 1
b) 5
c) 10
1
Kids should not have apnoeas
10
Neostigmine should be avoided in patients with
A Fredricks ataxia (frataxin)
B hypokalaemia FPP
C Becker MD/ Duschenes MD (dystrophin)
D Myotonia congenita (Cl channel)
hFPP and MC both contraindicated??
Myotonia congenita: • Myotonic Dystrophy Foundation: Neostigmine is contraindicated due to its ability to induce myotonic rigidity. • OpenAnesthesia: Avoid neostigmine as it exacerbates myotonia. • Anesthesia Considerations: Cholinesterase inhibitors (e.g., neostigmine) trigger myotonic contractures.
##
Neostigmine should be avoided in patients with D. Myotonia congenita (Cl channel).
The strongest evidence from multiple authoritative sources highlights:
- Neostigmine triggers myotonic crises (prolonged muscle rigidity) in chloride channel myotonia due to its acetylcholinesterase inhibition, which exacerbates abnormal muscle membrane excitability.
- Guidelines explicitly contraindicate neostigmine reversal in myotonic disorders, including myotonia congenita, due to this risk[2][4][7][10].
-
C. Becker/Duchenne MD (dystrophin):
- While some sources note neostigmine may worsen rhabdomyolysis risk in dystrophinopathies[4][9], others state antagonism with neostigmine is feasible[3]. This creates ambiguity, making it less definitive than D.
- Current recommendations prefer sugammadex for reversal but do not universally prohibit neostigmine in dystrophinopathies[3][12].
-
B. Hypokalaemic Familial Periodic Paralysis:
- No direct contraindication to neostigmine exists in the provided sources.
-
A. Friedreich Ataxia (frataxin):
- No evidence of neostigmine contraindication.
-
Myotonia congenita:
- Myotonic Dystrophy Foundation: Neostigmine is contraindicated due to its ability to induce myotonic rigidity[2][5].
- OpenAnesthesia: Avoid neostigmine as it exacerbates myotonia[10].
- Anesthesia Considerations: Cholinesterase inhibitors (e.g., neostigmine) trigger myotonic contractures[7].
Conclusion: The single correct answer is D, supported by unequivocal guidelines against neostigmine use in chloride channel myotonia.
Sources
[1] [PDF] Anaesthesia and the paediatric muscle disorders https://sajaa.co.za/index.php/sajaa/article/download/1090/1216
[2] [PDF] PRACTICAL SUGGESTIONS FOR THE ANESTHETIC … https://www.myotonic.org/sites/default/files/Anesthesia%20Guidelines.pdf
[3] [PDF] Anaesthesia recommendations for Duchenne muscular dystrophy https://www.orphananesthesia.eu/en/rare-diseases/published-guidelines/duchenne-muscular-dystrophy/809-duchenne-muscular-dystrophy-2/file.html
[4] European Neuromuscular Centre consensus statement on … https://pmc.ncbi.nlm.nih.gov/articles/PMC9826444/
[5] [PDF] PRACTICAL SUGGESTIONS FOR THE ANESTHETIC … https://www.myotonic.org/sites/default/files/MDF_LongForm_AnesGuidelines_01C.pdf
[6] [PDF] Beckers disease - OrphanAnesthesia https://www.orphananesthesia.eu/de/erkrankungen/handlungsempfehlungen/beckers-erkrankung/407-becker%E2%80%99s-disease-1/file.html
[7] Myotonic Dystrophy - Anesthesia Considerations https://www.anesthesiaconsiderations.com/myotonic-dystrophy-
[8] Medical Management - Duchenne Muscular Dystrophy (DMD) https://www.mda.org/disease/duchenne-muscular-dystrophy/medical-management
[9] A Review on the Anesthetic Management of Patients with … https://pmc.ncbi.nlm.nih.gov/articles/PMC10319043/
[10] Myotonic Dystrophy - OpenAnesthesia https://www.openanesthesia.org/keywords/myotonic-dystrophy/
[11] [PDF] Guideline on the clinical investigation of medicinal products for the … https://www.tga.gov.au/sites/default/files/2024-05/EMACHMP2369812011corr1%20GL%20on%20Duchenne%20Becker%20muscular%20dystCurrent%20CURRENT.PDF
[12] Anesthetic implications of muscular dystrophies - SciELO Colombia http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-33472018000300228
[13] [PDF] Anesthetic management of a patient with myotonia congenita https://www.apicareonline.com/index.php/APIC/article/download/1712/2616/
[14] S8251 - Sigma-Aldrich https://www.sigmaaldrich.com/US/en/search/s8251?focus=papers&page=1&perpage=30&sort=relevance&term=s8251&type=citation_search
[15] PROBLEMS OF ANESTHESIA IN PATIENTS WITH … https://www.sciencedirect.com/science/article/pii/S0889853705703576
[16] Neostigmine - StatPearls - NCBI Bookshelf https://www.ncbi.nlm.nih.gov/books/NBK470596/
[17] Muscular Dystrophy Guidelines - Medscape Reference https://emedicine.medscape.com/article/1259041-guidelines
[18] [PDF] Anaesthetic Management in Duchenne Muscular Dystrophy https://aacc.tums.ac.ir/index.php/aacc/article/download/411/597/
[19] [PDF] Anaesthetic guidance for patients with Myotonic Dystrophy https://www.nn.nhs.scot/smn/wp-content/uploads/sites/25/2023/07/NSD610-018.14-SMN-Anaesthetic-guidance-for-patients-with-Myotonic-Dystrophy.pdf
[20] New Becker muscular dystrophy drug on the horizon https://innovationdistrict.childrensnational.org/new-becker-muscular-dystrophy-drug-on-the-horizon/
11. A transjugular intrahepatic portosystemic shunt procedure is contraindicated in patients with
Hepatorenal syndrome
Refractory ascites
Severe TR
Variceal bleeding
Budd chiari
- Severe TR
- Severe PHTN (MPAP > 45)
- HF
- Multiple hep cysts
Contraindications: Absolute (heart failure, severe TR, severe pulm HTN (mean pulm pressures >45mmHg, multiple hepatic cysts, sepsis, biliary obstruction) Relative (HCC, obstruction of all hepatic veins, PV thrombosis, severe coagulopathy, thrombocytopenia < 20x10^9, prior encephalopathy, moderate pulmonary HTN)
BJA Ed 2016 - Anaesthesia for TIPS (https://academic.oup.com/bjaed/article/16/12/405/2632741)
12
- When confirming correct placement of an endotracheal tube, verifying the presence of sustained exhaled carbon dioxide requires all the
4 criteria
4 criteria
“following criteria to be met (Fig. 2; [93]):
1. Amplitude rises during exhalation and falls during inspiration.
2. Consistent or increasing amplitude over at least seven breaths [74, 91]
3. Peak amplitude more than 1 kPa (7.5 mmHg) above baseline [74, 94].
4. Reading is clinically appropriate.”
https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.15817
- **The dataset that was used to create the Eleveld TCI model did NOT include patients who are / have
“Neonate
Elderly
Liver
Renal
Obese”
Liver?
- The blood product that contains the highest concentration of citrate is
a) whole blood
b) platelet
c) plasmapheresis
d) platelet additive
Plasma
CITRATE:
Whole blood: 26g/l
Platelet(phoresis): 22g/l
Plasma (apheresis): 40g/l
Platelet additive: 0.3g/l
Red cells and albumin: NONE! SAGM”
https://www.lifeblood.com.au/sites/default/files/resource-library/2024-08/Blood_Component_Information_2.0_0.pdf
- During a new pandemic, an anaesthetist refuses to provide sedation for an elective operation due to concern that the procedure may hasten community spread of the disease. This is the ethical principle of
“Beneficence
Non-maleficence
Justice
Conscientious objection
Professional autonomy
“
Non Malef
Patients brought to the hospital are at risk of spreading and contracting disease. The principle of non-maleficence, often referred to as the “do no harm” principle, strives to minimize the risk of harm to a patient, and argues that any procedure whose anticipated harms outweigh the expected benefits should not be performed [20]. During the current pandemic, the decision to suspend non-urgent elective procedures was made in part to protect surgical patients from disease transmission (i.e., harm). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082741
- The anaesthetic technique associated with the highest rate of postprocedure patency of a newly-created arteriovenous fistula is
BP block
LA by surgeons
BP block
Long-Term Functional Patency and Cost-Effectiveness of Arteriovenous Fistula Creation under Regional Anesthesia: a Randomized Controlled Trial
https://pubmed.ncbi.nlm.nih.gov/32709710/?utm_source=perplexity
Compared with local anesthesia, regional anesthesia significantly improved both primary and functional AVF patency at 1 year and is cost-effective.
Clinical trial registry name and registration number: Local Anaesthesia versus Regional Block for Arteriovenous Fistulae, NCT01706354.
17. The image below shows the arterial pressure (red, upper line) and balloon pressure (blue, lower line) from an intra-aortic balloon pump set at 1:2 augmentation. The point of the waveform indicated by the large green arrow is called
https://derangedphysiology.com/main/required-reading/cardiothoracic-intensive-care/Chapter%20634/normal-iabp-waveform
ABC anaes
18. A patient’s true arterial oxygen saturation will be lower than a pulse oximeter reading in the presence of
COHB
Methylene blue
Sickle cell
SaO2 < SpO2
COHb
(CarboxyHb)
(Miller)
Also:
Skin pigmentation if saO2 < 80% (Miller)
IABP (UTD)
Inc HbA1c (UTD)
19. Organ procurement after circulatory death is generally stood down if the time from cessation of cardiorespiratory support to circulatory death extends beyond
“30
60
90
180mins “
90 mins
Organ procurement after circulatory death in Australia is generally stood down if circulatory death does not occur within 90 minutes after withdrawal of cardiorespiratory support. This timeframe is based on nationally accepted guidelines and clinical protocols to ensure organ viability[3][6][10][13].
- 90-minute threshold: The Australian Donation after Circulatory Determination of Death (DCDD) guidelines specify that organs are typically only procured if circulatory death occurs within 90 minutes of withdrawing life-sustaining treatment[10][13].
- Organ-specific viability: While the stand-down period is 90 minutes, individual organs have shorter maximum warm ischemic tolerances (e.g., 30 minutes for liver/pancreas, 60 minutes for kidneys, and 90 minutes for lungs)[3][20].
- Abandonment criteria: If death does not occur within this window, organ procurement is halted, though tissue donation may still proceed after death[3][6].
This approach balances ethical standards, organ viability, and clinical feasibility in alignment with Australian guidelines[10][13].
Sources
[1] [PDF] Organ Donation After Circulatory Death - NSW Health https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/GL2024_010.pdf
[2] Donation after circulatory death (DCD)—lung procurement - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8012413/
[3] PROTOCOL Organ and Tissue Donation and Procurement after … https://www.rch.org.au/picu/Donation_after_cardiac_death_protocol/
[4] [PDF] Untapped potential in Australian hospitals for organ donation after … https://www.mja.com.au/system/files/issues/207_07/10.5694mja16.01405.pdf
[5] Death and Organ Donation Statement - ANZICS https://www.anzics.org/death-and-organ-donation-app-content/
[6] Untapped potential in Australian hospitals for organ donation after … https://www.mja.com.au/journal/2017/207/7/untapped-potential-australian-hospitals-organ-donation-after-circulatory-death
[7] Best Practice Guideline for Donation after Circulatory Determination … https://www.donatelife.gov.au/for-healthcare-workers/clinical-guidelines-and-protocols/national-guideline-donation-after-circulatory-death
[8] [PDF] Clinical Guidelines for Organ Transplantation from Deceased Donors https://tsanz.com.au/storage/documents/TSANZ_Clinical_Guidelines_Version-111_13062023Final-Version.pdf
[9] Clinical guidelines and protocols - DonateLife https://www.donatelife.gov.au/for-healthcare-workers/clinical-guidelines-and-protocols
[10] [PDF] Donation after Circulatory Determination of Death (DCDD) in Australia https://www.donatelife.gov.au/media/best-practice-guideline-donation-after-circulatory-determination-death-australia-634-kb-pdf
[11] 2 Organ donor suitability - TSANZ https://tsanz.com.au/preview-page?p=6
[12] [PDF] The Statement on Death and Organ Donation | DonateLife https://www.donatelife.gov.au/media/anzics-statement-death-and-organ-donation-edition-41
[13] Organ donation after circulatory death (DCD) - NSW Health https://www.health.nsw.gov.au/organdonation/Pages/donation-following-circulatory-death.aspx
[14] Donation after Circulatory Death (DCD) - LITFL https://litfl.com/donation-after-circulatory-death-dcd/
[15] [PDF] Section 3 - Deceased Organ Donor Pathway - ANZDATA https://www.anzdata.org.au/wp-content/uploads/2022/05/s03_pathway_2021_ar_2022_v2.0_section_20220521_final.pdf
[16] “The Cadaveric Organ Shortage: a result of Australia’s … - AustLII http://www8.austlii.edu.au/cgi-bin/viewdoc/au/journals/CanLawRw/2022/7.html
[17] [PDF] Understanding death and donation | DonateLife https://www.donatelife.gov.au/media/otandfssunderstanding-death-donation-july-2021pdf
[18] [PDF] Deceased Organ Donation Pathway - ANZDATA https://www.anzdata.org.au/wp-content/uploads/2017/10/c03_pathway_v1.0_20171027.pdf
[19] [PDF] Ethical guidelines for organ transplantation from deceased donors https://www.nhmrc.gov.au/sites/default/files/documents/attachments/NHMRC-ethical-guidelines-organ-transplant.pdf
[20] Donation after circulatory determination of death https://derangedphysiology.com/main/required-reading/organ-and-tissue-donation/Chapter-616/donation-after-circulatory-determination-death
20. The rank of volatile anaesthetic agents from highest to lowest derived global warming potential over 100 years (GWP100) is
GWP 100 kills DINS (dinos)
The Global Warming Potential (GWP) 100 of inhaled anesthetics is a measure of how much each gas contributes to global warming over a 100-year period
D 2500 (20x sevo) (5x iso)
I 500 (2x n2o)
N 250 (2x sevo)
S 125
https://www.asahq.org/about-asa/governance-and-committees/asa-committees/environmental-sustainability/greening-the-operating-room/inhaled-anesthetics
21. A characteristic feature of postoperative visual loss due to posterior ischaemic optic neuropathy is
a) Resolves w/in 24h
b) Normal fundo
c) Painful
d) Visual inattention
e) No loss papillary reflex
a) Resolves w/in 24h (no)
b) Normal fundo
c) Painful (no)
d) Visual inattention (no, just normally bilat absent vision)
e) No loss papillary reflex (incorrect, papillary reflex is gone)
AION = painless, progressive VL, oedematous optic disc (PV+OF)
PION = painless, acute, unilateral or bilateral VL, normal optic disc (least blood flow = vulnerable)
22. The bipolar leads of a 12-lead electrocardiogram are
ALSO
what are the unipolar leads?
whare are the augmented leads?
Bipolar = 2 leads (+ and - electrode)
I, II, III
Limb leads = RA LA LL RL
6 limb lead = I/II/III + aVR/L/F
Chest/Praecordial leads = V1-V6
(6 unipolar praecordial lead)
“A”ugmented Lead = aVL, aVR, aVF
measure electrical activity between one limb and a single electrode
One lead = unipolar
R/L/F = POSITIVE electrode position
5 lead ECG = 5 electrodes
smoke over fire
white is right, snow over tree (Green/ground)
chocolate to the heart (chest)
I II III aVR/L/F and V
–> improve STE reading
12 lead ECG = 10 electrodes
- 4 on limbs; 6 praecordium
Plane = cross sectional view
Lead = view b/w + and - pole
https://www.ausmed.com.au/learn/articles/5-lead-ecg
23. The local anaesthetic with the lowest CC/CNS ratio (ratio of the drug dose required to cause cardiac collapse to the drug dose required to cause seizure) is
Bupiv
357
BRL
24. The time for reversal of therapeutic dabigatran after administration of idarucizumab 5 g is
“a) 5min
b) 15min
c) 30min
d) 60min
e) 120min”
UTD: Anticoagulant effect completely reversed within 15min
a) 5 min
Rationale:
Idarucizumab, a monoclonal antibody fragment, rapidly and completely reverses the anticoagulant effects of dabigatran by binding to it with high affinity. Clinical studies, including the pivotal RE-VERSE AD trial, demonstrate that coagulation parameters (e.g., dilute thrombin time, ecarin clotting time) normalize within minutes of administering the 5 g dose[1][2][8]. For example:
- RE-VERSE AD Interim Analysis: In patients requiring urgent procedures, complete reversal occurred within minutes in 98.7% of cases based on dTT and 82.2% based on ECT, with median time to surgery initiation <2 hours in most cases[1][8].
- Pharmacodynamic Studies: Idarucizumab normalizes clotting times (dTT, ECT, aPTT) within 5 minutes of administration, as shown in controlled volunteer trials and animal models[4][10][11].
- Mechanism of Action: The rapid on-rate of idarucizumab binding to dabigatran ensures immediate neutralization of its anticoagulant activity, with unbound dabigatran concentrations dropping below therapeutic thresholds within 5 minutes[10][11].
While bleeding cessation or procedural hemostasis may take longer (e.g., median 2.5–11.4 hours for bleeding cessation), the reversal of anticoagulation itself is nearly instantaneous[2][8]. Thus, the correct answer is 5 minutes.
Answer: a) 5 min
Sources:[1][2][4][8][10][11]
Citations:
[1] https://pubmed.ncbi.nlm.nih.gov/31599808/
[2] https://pubmed.ncbi.nlm.nih.gov/26095746/
[3] https://pubmed.ncbi.nlm.nih.gov/30586692/
[4] https://www.medsafe.govt.nz/profs/datasheet/p/praxbindinj.pdf
[5] https://australianprescriber.tg.org.au/articles/idarucizumab.html
[6] https://www.nps.org.au/news/idarucizumab-praxbind-for-dabigatran-pradaxa-reversal-what-you-should-know
[7] https://pmc.ncbi.nlm.nih.gov/articles/PMC7237558/
[8] https://pubmed.ncbi.nlm.nih.gov/28693366/
[9] https://www.seslhd.health.nsw.gov.au/sites/default/files/documents/SESLHDMG%20110%20-%20Idarucizumab%20in%20Urgent%20Dabigatran%20Reversal%20-%20Medicine%20Guideline.pdf
[10] https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.115.019628
[11] https://www.tga.gov.au/sites/default/files/auspar-idarucizumab-161025-pi.pdf
[12] https://www.nice.org.uk/advice/esnm73/resources/reversal-of-the-anticoagulant-effect-of-dabigatran-idarucizumab-pdf-1502681164008901
[13] https://www.tga.gov.au/sites/default/files/auspar-idarucizumab-161025.docx
[14] https://www.thebottomline.org.uk/summaries/icm/idarucizumab-for-dabigatran-reversal/
[15] https://www.thewaltoncentre.nhs.uk/Downloads/disclosure-log/2022/January-2022/FOI5020_Dabigatran%20Reversal%20with%20Idarucizumab%20Guideline_Information%20Governance.pdf
[16] https://pubmed.ncbi.nlm.nih.gov/25789661/
[17] https://www.health.wa.gov.au/~/media/Files/Corporate/general%20documents/WATAG/Idarucizumab-for-reversal.pdf